Details
OMEROS CORPORATION PROVIDES UPDATE ON INTERIM ANALYSIS OF ARTEMIS-IGAN PHASE 3 TRIAL OF NARSOPLIMAB IN IGA NEPHROPATHY The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials
Comment
OMEROS CORPORATION PROVIDES UPDATE ON INTERIM ANALYSIS OF ARTEMIS-IGAN PHASE 3 TRIAL OF NARSOPLIMAB IN IGA NEPHROPATHY The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials
